|
GSK PLC on Saturday said the US Food & Drug Administration has approved its vaccine against five common disease-causing serogroups of Neisseria meningitidis. The FDA approved Penmenvy for use in adolescents and young adults from 10 to 25 years old. It reduces the number injections required by targeting five major serogroups of meningitidis that cause invasive meningococcal disease. IMD can lead to death for up to one in six of those who contract it in as little as 24 hours from onset. Penmenvy combines the antigenic components of two existing meningococcal vaccines from GSK: Bexsero and Menveo. GSK shares were down 1.0% to 1,421.00 pence early Monday in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
